Skip to main content

Table 1 Clinical characteristics of early hepatocellular carcinoma patients treated with RFA-TACE or with SR before and after propensity score matching

From: Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods

Variables Before propensity score matching After propensity score matching
RFA-TACE
(n = 176)
SR
(n = 125)
P value RFA-TACE
(n = 66)
SR
(n = 66)
P value
No. (%) No. (%) No. (%) No. (%)
Age (years)
  < 65 90 (51.1) 74 (59.2) 0.17 35 (53.0) 35 (53.0) 1.0
  > 65 86 (48.9) 51 (40.8)   31 (47.0) 31 (47.0)  
 Mean + SD 64.0 + 10.4 62.2 + 10.7   63.7 + 12.6 64.0 + 10.3  
Gender
 Male 109 (61.9) 87 (69.6) 0.17 47 (68.1) 47 (68.1) 1.0
 Female 67 (38.1) 38 (30.4)   22 (31.9) 22 (31.9)  
Child-Pugh
 A 162 (92.1) 122 (97.6) 0.04 61 (92.4) 65( 98.5) 0.10
 B 14 (7.9) 3 (2.4)   5 (7.6) 1 (1.5)  
Etiology
 Seronegative 17 (9.7) 21 (16.8) 0.008 8 (12.1) 7 (10.6) 0.40
 HBV 70 (39.8) 65 (52.0)   34 (51.5) 28 (42.4)  
 HCV 82 (46.6) 36 (28.8)   22 (33.3) 29 (43.9)  
 HBV + HCV 7 (4.0) 3 (2.4)   2 (3.03) 2 (3.03)  
Ishak score-fibrosis
 1–3 52 (29.6) 29 (23.2) 0.22 16 (24.2) 14 (21.2) 0.67
 4–6 124 (70.4) 96 (76.8)   50 (75.8) 52 (78.8)  
Edmonson grading
 I and II 137 (90.7) 103 (83.1) 0.06 50 (89.3) 48 (85.7) 0.56
 III and IV 14 (9.3) 21 (16.9)   6 (10.7) 8 (14.3)  
Diabetes
 No 123 (69.9) 92 (73.6) 0.48 47 (71.2) 48 (72.7) 0.85
 Yes 53 (30.1) 33 (26.4)   19 (28.8) 18 (27.3)  
CSPH
 No 131 (74.4) 99 (79.2) 0.34 55 (79.7) 53 (76.8) 0.69
 Yes 45 (25.6) 26 (20.8)   14 (20.3) 16 (23.2)  
No. of nodules
 Single 126 (71.6) 104 (83.2) 0.02 58 (87.9) 56 (84.9) 0.56
  > 2 nodules 50 (28.4) 21 (16.8)   8 (12.1) 10 (15.1)  
Creatinine (mg/dL)
  <  1.5 159 (90.3) 120 (96.0) 0.07 62 (93.9) 64 (97.0) 0.41
  > 1.5 17 (9.7) 5 (4.00)   4 (6.1) 2 (3.0)  
AFP level (ng/mL)
  < 20 96 (54.6) 85 (68.0) 0.02 40 (60.6) 42 (63.6) 0.59
  > 20 80 (45.4) 40 (32.0)   26 (39.4) 24 (36.4)  
Albumin (mg/dL)
  > 3.0 166 (94.3) 123 (98.4) 0.07 61 (92.4) 65 (98.5) 0.05
  < 3.0 10 (5.7) 2 (1.6)   5 (7.6) 1 (1.5)  
Total bilirubin (mg/dL)
  <  1.5 161 (91.5) 117 (95.1) 0.22 60 (90.9) 61 (92.4) 0.74
  > 1.5 15 (8.5) 6 (4.9)   6 (9.1) 5 (7.6)  
Prothrombin time (INR)
  < 1.3 164 (93.2) 122 (97.6) 0.11 62 (93.9) 65 (98.5) 0.18
  > 1.3 12 (6.8) 3 (2.4)   4 (6.1) 1 (1.5)  
AST (IU/L)
  < 80 139 (79.0) 106 (84.8) 0.20 56 (84.9) 55 (83.3) 0.81
  > 80 37 (21.0) 19 (15.2)   10 (15.1) 11 (16.7)  
ALT (IU/L)
  < 80 140 (79.6) 99 (79.2) 0.94 54 (81.8) 53 (80.3) 0.81
  > 80 36 (20.5) 26 (20.8)   12 (18.2) 13 (19.7)  
Size (cm)
  < 3.0 129 (73.3) 50 (40.0) < 0.0001 38 (57.6) 37 (56.1) 0.76
  > 3.0 47 (26.7) 75 (60.0)   28 (42.4) 29 (43.9)  
 Mean + SD 24.9 + 9.0 32.6 + 11.5   27.5 + 10.2 28.3 + 10.8  
BCLC stage
 0 47 (26.7) 18 (14.4) 0.01 17 (25.8) 16 (24.2) 0.71
 A 129 (73.3) 109 (85.6)   49 (74.2) 50 (75.8)  
  1. CSPH clinically significant portal hypertension, AFP Alpha-fetoprotein, ALT Alanine aminotransferase, AST Aspartate aminotransferase, HBV hepatitis B virus, HCV hepatitis C virus, INR International normalized ratio, BCLC Barcelona-Clınic Liver Cancer staging system, RFA-TACE Radiofrequency ablation with or without transcatheter arterial chemoembolization, SR surgical resection